Physician profile
Salar Rafieetary
NPI 1174052237
$36,769.87
in general payments reported to CMS, 2019-2025
19 companies · $11K in 2025
The $11K reported for 2025 was more than what 91% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $407 · 2022: $952 · 2023: $530 · 2024: $24K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Travel and Lodging: $5,097 · Food and Beverage: $2,068 · Honoraria: $2,000 · Entertainment: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,000.00 |
| Travel and Lodging | $5,097.47 |
| Food and Beverage | $2,067.78 |
| Honoraria | $2,000.00 |
| Entertainment | $245.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $31,140.89 | 2023-2025 | Izervay |
| Optos, INC. | $2,901.56 | 2024-2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Apellis Pharmaceuticals, INC. | $616.60 | 2022-2025 | Syfovre |
| Mallinckrodt Hospital Products INC. | $536.84 | 2021-2025 | Acthar |
| Harrow Eye, LLC | $237.41 | 2023 | Iheezo |
| Eyepoint US, INC. | $220.50 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $216.41 | 2021-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $208.43 | 2022-2024 | Vabysmo |
| Alcon Vision LLC | $146.00 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $121.30 | 2025 | Iluvien, Yutiq |
| Novartis Pharmaceuticals Corporation | $103.93 | 2022 | |
| Sun Pharmaceutical Industries INC. | $103.12 | 2024 | |
| Abbvie INC. | $50.55 | 2022-2024 | |
| Alimera Sciences, INC. | $46.34 | 2024 | Iluvien, Yutiq |
| Neurotech Pharmaceuticals, INC. | $28.30 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $25.80 | 2023 | |
| Bausch & Lomb Americas INC. | $25.39 | 2025 | Xipere, Visudyne |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21.89 | 2021 | |
| Allergan, INC. | $18.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salar Rafieetary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.